Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma

Part of paid clinical trials in Sacramento, California.

Sponsor
University of California, Davis
Study ID
NCT07145112
Phase
PHASE1
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Laser interstitial thermal therapy — PROCEDURE
    MRI guided laser
  • Lomustine — DRUG
    Given orally (PO)

Study Details

This is a phase 1 study evaluating the safety and feasibility of laser interstitial thermal therapy (LITT) followed by lomustine (CCNU) for recurrent glioblastoma in adults. The primary aim is to evaluate the safety of the combination of LITT plus lomustine based on the assessment of treatment-related adverse events and the feasibility of completing LITT + lomustine in the proposed timeframe. The secondary aim is to assess overall survival for up to 2 years after the first dose of lomustine.

Key Dates

Start date
Oct 1, 2025
Status verified
Oct 2025
Primary completion
Jul 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Laser interstitial thermal therapy (LITT) + Lomustine (CCNU)
    Laser interstitial thermal therapy (LITT) + Lomustine (CCNU)

Primary Outcome Measure

Safety of the combination of Laser Interstitial Thermal Therapy (LITT) and lomustine in patients with recurrent glioblastoma. [ Time Frame: Up to 6 weeks after first dose of lomustine ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California Davis Comprehensive Cancer CenterSacramentoCalifornia95827
Orwa Aboud, MD, PhD
916-734-3772
Orwa Aboud, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Sacramento, CA

By condition

Related Studies